Sumoylation is an essential post-translational modification that is catalysed by a small
number of modifying enzymes but regulates thousands of target proteins in a dynamic …

Abstract The NCI-MATCH (Molecular Analysis for Therapy Choice) trial (NCT02465060) was
launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial …

Immune-checkpoint blockade (ICB) therapies represent a paradigm shift in the treatment of
human cancers; however, it remains incompletely understood how tumor-reactive T cells …

Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a
formidable challenge due to its immunosuppressive microenvironment, thereby confounding …

Predicting the clinical response to chemotherapeutic or targeted treatment in patients with
locally advanced or metastatic lung cancer requires an accurate and affordable tool. Tumor …

Under the selective pressure of therapy, tumours dynamically evolve multiple adaptive
mechanisms that make static interrogation of genomic alterations insufficient to guide …

Purpose: KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal
adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to …

Background Breast cancer (BC) is the second most frequent type of cancer in the world and
most common among women, configuring a major challenge to global health. BC is a …

Prognostically relevant RNA expression states exist in pancreatic ductal adenocarcinoma
(PDAC), but our understanding of their drivers, stability, and relationship to therapeutic …

Increasing disease-related proteins have been identified as novel therapeutic targets.
Macrocycles are emerging as potential solutions, bridging the gap between conventional …